- cafead   Aug 06, 2024 at 11:22: AM
via Big Pharmas remain stuck to the idea of molecular glue degraders. The latest company to see an opportunity is Japan’s Eisai, which has signed a $1.5 billion biobucks pact with SEED Therapeutics for undisclosed neurodegeneration and oncology targets.
article source
article source